Is the reduction of plasma endothelin levels in the acute and subacute phases of myocardial infarction a beneficial effect of early ACE-inhibition treatment?;La riduzione dei livelli plasmatici dell'endotelina nelle fasi acute e sub-acute dell'infarto miocardico e uno degli effetti benefici del precoce trattamento con ACE-inibitori?

Giornale Italiano di Cardiologia

Volumn 26, Issue 7, 1996, Pages 673-680

  Di Pasquale, Pietro ^a,d   Bucca, Vincenzo ^a   Scalzo, Sebastiano ^a   Cannizzaro, Sergio ^a   Longo, Anna M ^a   Alessi, Vincenza ^a   D'Amato, Michele ^a   Manusia, Franco ^b   Magatti, Maria F ^c  

^a Ospedale GF Ingrassia   (Italy)

^b MISERICORDIA HOSPITAL   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

^d NONE

Author keywords

ACE inhibitors; Endothelin; Myocardial Infarction; Thrombolysis

Indexed keywords

CAPTOPRIL; ENDOTHELIN 1; PLACEBO;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CREATINE KINASE; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0030470396     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Yanagisawa M, Kurihara H, Kimura S et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A: Contribution of endogenous endothelins to the extension of myocardial infarct size in rats. Circ Res 1991; 69: 370-377.
3. Omland T, Lie RT, Aakvaag T, Dickstein K: Plasma endothelin determination as a prognostic in- dicator of 1 year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
4. Stewart DJ, Kubac G, Costello KG, Cernacek P: Increased plasma endothelin-1 in the early Hours of acute myocardial infarction. J Am Coll Cardiol 1991; 18: 38-43.
5. Tomoda H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993; 125: 667-671.
6. Ray SG, McMurray JJ, Dargie HJ: Circulating endothelin in acute ischaemic syndromes. Br Heart J 1992; 67: 383-386.
7. Leichleitner P, Genser N, Maier J, Artner- Dworzak E, Dienstl F, Puschendorf B: Endothelin-1 in patients with complicated myocardial infarction. Clin Investig 1992; 70: 1070-1072.
8. Leichleitner P, Genser N, Nair J et al: Immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem 1993; 39: 955-959.
9. Tahara A, Kohno M, Yanagi S et al: Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplastic. Metabolism 1991; 40: 1235-1237.
10. Di Pasquale P, Paterna S, Parrinello G et al: Does plasma endothelin during thrombolysis depend on infarct size? A pilot study. Cardiog Drugs Ther 1995; 9: 831-832.
11. Di Pasquale P, Paterna S, Parrinello G et al: Plasma concentrations of endothelin-1 during thrombolysis, in patients with anterior, inferior myocardial infarction and unstable angina. Nutr Metab Cardiovasc Dis 1996; (in press).
12. Nakamura M, Arakawa N, Yoshida H et al: Increased plasma endothelin concentrations in patients with acute heart failure after myocardial infarction. JPN Circ J 1993; 57: 371-378.
13. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox CA: Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994; 72: 436-441.
14. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A: Endothelin in myocardial infarction. Nature 1990; 344: 144.
15. Qiu S, Theroux P, Mardi M, Solymon BC: Plasma endothelin-1 levels in stable and unstable angina. Cardiology 1993; 82: 12-19.
16. Rainer MA, Ute WL, Lars H: Increased plasma endothelin in patients with hyperlipoproteinemia and stable or unstable angina (Abstract). Circulation 1990; 82 (Suppl III): III-248.
17. Stewart JT, Nisber JA, Davies MJ: Plasma endothelin in coronary venous blood from patients with either stable or unstable angina. Br Heart J 1991; 66: 7-9.
18. Yang Z, Richard V, Von Seggesser C et al: Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82: 188-195.
19. Kiowski W, Luscher TF, Linder L, Buhler F: Endothelin-1 induced vasoconstriction in humans. Circulation 1991; 83: 469-475.
20. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J: Endothelin in heart failure normalizes during treatment with angiotensin converting enzyme inhibition fosinopril (Abstract). Circulation 1995; 92: 1-208.
21. Di Pasquale P, Paterna S, Parrinello G et al: Effects of captopril on plasma endothelin-1 during thrombolysis: preliminary findings. Cardiov Drug Ther 1995; 9: 359-360.
22. Di Pasquale P, Paterna S, Parrinello G et al: Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion. Int J Cardiol 1995; 51: 131-135.
23. Momose N, Fuhuo K, Morimoto S, Ogihara T: Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension 1993; 21: 921-924.
24. Di Pasquale P, Bucca V, Giuliano P, Maringhini G, Scalzo S, Paterna S: Advantages of immediate two-dimensional echocardiography in patients with acute cardiac ischemic events. Int J Cardiol 1995; 51: 85-91.
25. Suzuki N, Matsumoto H, Kitada C, Masaki T, Fujino M: A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods 1989; 118: 245-250.
26. Tomoda H: Coronary thrombolysis and endothelin-1 release. Angiology 1993; 44: 441-446.
27. Liu J, Chen R, Casley DJ, Nayler WG: Ischemia and reperfusion increase 125-I-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol (Heart Circ Physiol) 1990; 258: H829-835.
28. Uemasu J, Munemura C, Fujhara M, Kawasaki H: Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin Nephrol 1994; 41: 150-152.
29. Teerlink JR, Hess P, Clozel M, Clozel JP, Hoffman F: Role of endothelin in conscious rats with chronic heart failure (Abstract). Circulation 1994; 90: 1-261.
30. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J: Plasma endothelin-1 in chronic heart failure: a predictor of cardiac death? (Abstract). Circulation 1994; 90: I-379.
31. Cimminiello C, Soncini M, Casazza F: Plasma endothelin as an indipendent predictor of mortality (Letter). Circulation 1995; 91: 909.
32. Di Pasquale P, Paterna S, Cannizzaro S, Bucca V: Does captopril treatment before thrombolysis in acute myocardial infarction attenuate reperfusion damage? Short-term and long-term effects. Int J Cardiol 1994; 43: 43-50.
33. Pfeffer MA, Braunwald E, Moyé LA et al for the SA VE investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992; 327: 669-677.
34. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
35. The Trace Study group: The trandolapril Cardiac Evaluation (TRACE) Study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994; 73: 44C-50C.
36. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H: For the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678-684.
37. Gruppo Italiano per lo Studio delta Soprawivenza nell'Infarto Miocardico, GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1995; 343: 1115-1122.
38. ISIS-4 Collaborative Group, ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
39. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13674 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-687.
40. Kingma JH, Van Gilst WH, Peels CH, Dambrink JHE, Verheugt FWA, Wielenga RP: Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994; 15: 898-907.
41. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction long-term evaluation (SMILE) Study investigators: The effects of the angiotensin converting enzyme inhibitor Zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-85.